Seeking Alpha

The proposed merger between Valeant Pharmaceuticals (VRX) and Actavis (ACT) is on hold after a...

The proposed merger between Valeant Pharmaceuticals (VRX) and Actavis (ACT) is on hold after a disagreement on the terms of the deal derails discussions, sources say. Should the deal eventually come to fruition, the combined market value of the two firms would be ~$35B. (Reuters)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs